[go: up one dir, main page]

WO2010128364A1 - Procédé pour la prévention ou le traitement d'une allergie au pollen de taxodiaceae - Google Patents

Procédé pour la prévention ou le traitement d'une allergie au pollen de taxodiaceae Download PDF

Info

Publication number
WO2010128364A1
WO2010128364A1 PCT/IB2009/053465 IB2009053465W WO2010128364A1 WO 2010128364 A1 WO2010128364 A1 WO 2010128364A1 IB 2009053465 W IB2009053465 W IB 2009053465W WO 2010128364 A1 WO2010128364 A1 WO 2010128364A1
Authority
WO
WIPO (PCT)
Prior art keywords
pollen
allergy
extract
taxodiaceae
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2009/053465
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stallergenes SA
Original Assignee
Stallergenes SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stallergenes SA filed Critical Stallergenes SA
Priority to PCT/IB2009/053465 priority Critical patent/WO2010128364A1/fr
Publication of WO2010128364A1 publication Critical patent/WO2010128364A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route

Definitions

  • the present invention relates to a method for treating Taxodiaceae pollen allergy, in particular Cryptomeria japonica pollen allergy.
  • Allergen-specific sublingual immunotherapy indeed represents a safe and efficient non invasive alternative to subcutaneous immunotherapy (Bahceciler et a/. (2005) Int. Arch. Allergy Immunol. 136:287-294) in particular for the treatment of type I respiratory allergies (Canonica & Passalacqua (2006) Allergy 61 :20-23, Wilson et al. (2005) Allergy 60:4-12).
  • the allergen is captured within the oral mucosa by Langerhans-like dendritic cells expressing high affinity IgE receptors, producing IL10 (interleukin 10) and TGF ⁇ and upregulating the indoleamine dioxygenase (IDO), suggesting that such cells are prone to induce tolerance.
  • IgE indoleamine dioxygenase
  • the present invention arises from the unexpected finding, by the present inventors, that extracts from Mountain cedar pollen (Juniperus ashei, belonging to the Cupressaceae family, mainly growing in Texas, USAJ are at least as potent as extracts from Cryptome ⁇ a japonica pollen for completely inhibiting IgE binding to Mountain cedar pollen (Juniperus ashei, belonging to the Cupressaceae family, mainly growing in Texas, USAJ are at least as potent as extracts from Cryptome ⁇ a japonica pollen for completely inhibiting IgE binding to
  • Betulaceae was predictive of the efficacy of a birch pollen extract for treating pollen allergy to pollen of other plants of the Betulaceae family. This indicates that Juniperus ashei pollen extracts can be used for inducing immune tolerance towards Cryptomeria japonica pollen allergens.
  • the present invention relates to the use of at least one extract or of at least one recombinant pollen allergen from a plant of the Cupressaceae family, for the manufacture of a medicament intended for preventing or treating Taxodiaceae pollen allergy in an individual, preferably by inducing allergen- specific immune tolerance towards Taxodiaceae pollen allergens.
  • the plant of the Cupressaceae family as defined above is of the Juniperus genus and more preferably of the Juniperus ashei species.
  • the extract as defined above is a pollen extract.
  • the extract is a protein extract.
  • the protein extract can notably be obtained by an aqueous extract of pollen, in particular with an ammonium bicarbonate solution, preferably at a concentration of 4 g/l.
  • the extract is preferably such that it contains pollen allergens.
  • the extract can be purified so as to contain essentially only pollen allergens. Procedures for obtaining extracts are well known to one of skill in the art and can be performed essentially as described in Hrabina et a/. (2003) Allergy 58:808-813 for Juniperus ashei extracts.
  • an "allergen” is a substance wh ich elicits the production of IgE antibodies in predisposed individuals. Similar definitions are presented in the following references: Clin. Exp. Allergy, No. 26, pp. 494-516
  • the pollen allergens comprised in the extract, or the recombinant pollen allergens are selected from Juniperus sabinoides or virginiana pollen allergens, such as Jun s I and Jun v I and Juniperus ashei pollen allergens, such as Jun a 1 , Jun a 2, and Jun a 3.
  • Juniperus sabinoides or virginiana pollen allergens such as Jun s I and Jun v I
  • Juniperus ashei pollen allergens such as Jun a 1 , Jun a 2, and Jun a 3.
  • the cloning and expression of Jun a 1 , Jun a 2, and Jun a 3 can be easily carried out by one of skill in the art and are notably respectively described in Midoro-Horiuti et al. (1999) J. Allergy CHn. Immunol. 104:613-7; Yokoyama et al. (2000) Biochem. Biophys. Res.
  • the Taxodiaceae pollen allergy as defined above is an allergy to pollen from a plant of the Cryptomeria genus, more preferably of the Cryptomeria japonica (i.e. Japanese cedar) species.
  • the allergic reaction is directed against pollen allergens of Cryptomeria japonica, such as Cry j 1 , Cry j 2, and Cry j 3.
  • polylen allergy notably encompasses pollinosis, and pollen-induced asthma.
  • Determining that the pollen allergy is a Taxodiaceae pollen allergy can be easily carried out by one of skill in the art, for instance by carrying skin prick test with pollen extract from a Taxodiaceae, in particular from a Cryptomeria, and more particularly from Cryptomeria japonica.
  • the individual as defined above has stayed in Japan for at least one week at a period of pollen emission by plants of the Taxodiaceae family, such as Cryptomeria japonica, and more preferably the individual is a Japanese resident, i.e. an individual whose main residence is in Japan.
  • the medicament further comprises another extract, in particular a pollen extract, or another recombinant pollen allergen from a plant.
  • the plant can notably be another Cupressaceae, such as Chamaecyparis obtuse (i.e. Japanese cypress) or a Taxodiaceae, such as Cryptomeria japonica.
  • the medicament as defined above is suitable for administration by the mucosal route, more preferably by the oromucosal route, and most preferably by the sublingual route.
  • the medicament is preferably formulated in a way suitable for such administration routes.
  • Mucosal administration denotes any administration method wherein the formulation in part or in full comes into contact with a mucosa.
  • Mucosa refers to the epithelial tissue that lines the internal cavities of the body.
  • the mucosal surface may be selected from the group consisting of a nasal, buccal, oral, vaginal, ocular, auditory, pulmonary tract, urethral, digestive tract, and rectal surface.
  • Oromucosal administration comprises any administration method, wherein the formulation in part or in full comes into contact with the mucosa of the oral cavity and/or the pharynx of the patient.
  • Oromucosal administration includes in particular sublingual, perlingual (i.e. through the tongue mucosa) and oral administrations.
  • the sublingual mucosa located on the underside of the tongue, facilitates capture of the antigen and adjuvant by Langerhans-like cells that migrate to draining lymph nodes to prime T lymphocytes.
  • a route of administration of particular interest is to keep the composition under the tongue a few minutes, e.g. about 2 minutes, before swallowing or spitting it out.
  • the medicaments according to the invention can be administered in various forms, such as dispersed forms, e.g. in suspensions or gels, or as dry forms, e.g. in powders, tablets, capsules, lyoc, or forms suitable to be administered in a metered-dosing device.
  • the medicament comprises a mucoadhesive carrier.
  • a mucoadhesive carrier enables close and prolonged contact with a mucosa, in particular a mucosa of the oral cavity, and more particularly the sublingual mucosa, thereby enhancing-antigen specific tolerance induction.
  • Preferred mucoadhesive carriers as defined herein notably comprise chitosan, polymers of maltodexthn or carboxymethylcellulose.
  • the medicament as defined above may further comprise at least one adjuvant and/or at least one pharmaceutically acceptable excipient.
  • the medicament as defined above comprises an adjuvant and/or a mucoadhesive carrier.
  • an "adjuvant” enhances antigen-specific tolerance induction.
  • Adjuvants have been used for many years to improve the host immune responses to, for example, vaccines.
  • the adjuvant as defined herein may include any conventional or exploratory, synthetic or biological adjuvant for vaccination, including heat-labile enterotoxin (LT), cholera-toxin (CT), cholera toxin B subunit (CTB), polymerised liposomes, mutant toxins, probiotic bacteria, saponins complexed to membrane protein antigens (immune stimulating complexes), pluronic polymers with mineral oil, killed mycobacteria in mineral oil, Freund's complete adjuvant, bacterial products, such as muramyl dipeptide (MDP) and lipopolysaccharide (LPS), as well as lipid A, or biological or synthetic ligands of Toll like receptors (eg TLR2, 4, 5, 7 or 9).
  • MDP muramyl dipeptide
  • LPS lipopolys
  • the term "pharmaceutically acceptable excipient” includes solvents, dispersion media, coatings, isotonic and absorption delaying agents, mucoadhesive excipients, and the like, that do not produce an adverse or other untoward reaction when administered to an animal, or a human, as appropriate. Excipients may further include, but are not limited to disintegrants, binders, lubricants, flavoring, colorants, preservatives.
  • Suitable disintegrants include dry starch, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, stearic monoglyceride, lactose, as well as cross-linked polyvinylpyrrolidones, such as crospovidone (e.g., PolyplasdoneTM.
  • XL which may be obtained from GAF
  • cross-l inked carboxylic methylcelluloses such as croscarmelose (e.g., Ac-di-solTM, which may be obtained from FMC), alginic acid, and sodium carboxymethyl starches (e.g., ExplotabTM, which may be obtained from Edward Medell Co., Inc.), methylcellulose, agar bentonite and alginic acid.
  • Binders if used, are those that enhance adhesion. Examples of such binders include, but are not limited to, starch, gelatin and sugars such as sucrose, dextrose, molasses, and lactose.
  • Preferred lubricants are stearates and stearic acid. Lactose, mannitol, and croscarmelose are preferred excipients.
  • Figure 1 represents inhibition patterns obtained with the sera from a French patient allergic to cypress pollen. Cryptomeria japonica proteins were resolved by SDS Page. Proteins were transferred onto a nitrocellulose membrane, cut in 3 different strips (lanes 1 , 2 and 3) and incubated with either the serum from a
  • Example 1 Capacity of Juniperus ashei pollen allergens to inhibit the IgE binding of sera from a French cypress allergic patient on Cryptomeria japonica pollen allergens
  • the objective of the experiment was to study the capacity of Juniperus ashei pollen allergens to inhibit the IgE binding, on Cryptomeria japonica pollen allergens, of sera from a French patient allergic to cypress, by Western-blot.
  • Cryptomeria japonica proteins from a pollen extract obtained with sodium bicarbonate were resolved by SDS-Page.
  • Proteins were transferred onto a nitrocellulose membrane, cut in 3 different strips (lanes 1 , 2 and 3) and incubated with either a serum from a French patient allergic to cypress pollen properly diluted (lane 1 ), the serum previously incubated with Cryptomeria japonica pollen extract in excess (self inhibition, lane 2), and the serum previously incubated with Juniperus ashei pollen extract obtained with sodium bicarbonate (for example as described by Hrabina et al. (2003) Allergy 58:808-813) in excess (lane 3).
  • luminescence signals were detected and quantified using a highly sensitive Chemismart 2000 camera.
  • the results are shown in Figure 1.
  • the magnitude of signal in lane 1 is 100 %.
  • the signal in lane 2 (self inhibition control) is equal to 0 %.
  • the signal in lane 3 is equal to 0 % in presence of Juniperus ashei pollen extract as inhibitor which indicates that Juniperus ashei pollen allergens totally inhibit the binding of allergen-specific IgEs to Cryptomeria japonica pollen allergens. Accordingly, Juniperus ashei pollen extract is useful for treating allergy to Cryptomeria japonica pollen.
  • Example 2 Capacity of Juniperus ashei pollen allergens to inhibit the IgE bind ing of sera from 22 Cryptomeria japonica allergic patients on Cryptomeria japonica pollen allergens
  • a Western-blot study similar to that of Example 1 is performed, Cryptomeria japonica proteins from a pollen extract are resolved by SDS-Page.
  • Proteins are transferred onto a nitrocellulose membrane, cut in 3 different strips (lanes 1 , 2 and 3) and incubated with either a serum from a Japanese patient allergic to Japanese cedar pollen properly diluted (lane 1 ), the serum previously incubated with Cryptomeria japonica pollen extract in excess (self inhibition, lane 2), and the serum previously incubated with Juniperus ashei pollen extract in excess (lane 3).
  • luminescence signals are detected and quantified using a highly sensitive Chemismart 2000 camera. The results show that Juniperus ashei pollen allergens totally inhibit the binding of Cryptomeria yapon/ca-reactive IgE to Cryptomeria japonica pollen allergens.
  • both western blot experiments an Elisa-inhibition assay were performed using sera from Japanese patients. Briefly, the wells of an ELISA microtitration plate are coated with Cryptomeria japonica pollen allergens, and filled with mixtures of the serum from a Japanese patient previously incubated with
  • Cryptomeria japonica pollen extract at varying concentrations and the serum previously incubated with Juniperus ashei pollen extract at varying concentration.
  • the percentage of inhibition of IgE binding to the coated allergens is then determined for each mixture, and two curves plotting the percentage of inhibition vs the respective concentrations of Cryptomeria japonica or Juniperus ashei pollen extracts in the mixtures are established.
  • Juniperus ashei pollen extracts can be used for treating Cryptomeria japonica pollen allergy when essentially 100% inhibition, parallel curves, and, optionally, concentrations of Juniperus ashei pollen extracts lower than that of Cryptomeria japonica, to achieve the same percentage of inhibition, are obtained.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne l'utilisation d'au moins un extrait ou d'au moins un allergène recombinant provenant d'une plante de la famille Cupressaceae, pour la fabrication d'un médicament destiné à prévenir ou à traiter une allergie au pollen de Taxodiaceae chez un individu.
PCT/IB2009/053465 2009-05-04 2009-05-04 Procédé pour la prévention ou le traitement d'une allergie au pollen de taxodiaceae Ceased WO2010128364A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2009/053465 WO2010128364A1 (fr) 2009-05-04 2009-05-04 Procédé pour la prévention ou le traitement d'une allergie au pollen de taxodiaceae

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2009/053465 WO2010128364A1 (fr) 2009-05-04 2009-05-04 Procédé pour la prévention ou le traitement d'une allergie au pollen de taxodiaceae

Publications (1)

Publication Number Publication Date
WO2010128364A1 true WO2010128364A1 (fr) 2010-11-11

Family

ID=41383754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/053465 Ceased WO2010128364A1 (fr) 2009-05-04 2009-05-04 Procédé pour la prévention ou le traitement d'une allergie au pollen de taxodiaceae

Country Status (1)

Country Link
WO (1) WO2010128364A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2952200A1 (fr) 2014-06-04 2015-12-09 Alk-Abelló A/S Allergène pour le traitement prophylactique d'une allergie
US9271899B2 (en) 2010-04-30 2016-03-01 Allovate, Llc Methods, articles and kits for allergic desensitization, via the oral mucosa
US9724271B2 (en) 2010-04-30 2017-08-08 Allovate, Llc Methods and articles for preventing or reducing risk of developing a hyperallergenic immune system
US10967059B2 (en) 2013-09-19 2021-04-06 Allovate, Llc Toothpaste for delivery of allergens to oral mucosa

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0960887A1 (fr) * 1996-06-14 1999-12-01 Meiji Milk Products Company Limited PEPTIDE ANTIGENE Ly

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0960887A1 (fr) * 1996-06-14 1999-12-01 Meiji Milk Products Company Limited PEPTIDE ANTIGENE Ly

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ITO Y ET AL: "Clinical effects of immunotherapy on Japanese cedar pollinosis in the season of cedar and cypress pollination.", AURIS, NASUS, LARYNX APR 1997, vol. 24, no. 2, April 1997 (1997-04-01), pages 163 - 170, XP002561877, ISSN: 0385-8146 *
OKUBO KIMIHIRO ET AL: "A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis.", ALLERGOLOGY INTERNATIONAL : OFFICIAL JOURNAL OF THE JAPANESE SOCIETY OF ALLERGOLOGY SEP 2008, vol. 57, no. 3, September 2008 (2008-09-01), pages 265 - 275, XP002561878, ISSN: 1323-8930 *
PANZANI R ET AL: "Cross-reactivity between the pollens of Cupressus sempervirens (common cypress) and of Cryptomeria japonica (Japanese cedar).", ANNALS OF ALLERGY JUL 1986, vol. 57, no. 1, July 1986 (1986-07-01), pages 26 - 30, XP008116065, ISSN: 0003-4738 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9271899B2 (en) 2010-04-30 2016-03-01 Allovate, Llc Methods, articles and kits for allergic desensitization, via the oral mucosa
US9724271B2 (en) 2010-04-30 2017-08-08 Allovate, Llc Methods and articles for preventing or reducing risk of developing a hyperallergenic immune system
US10967059B2 (en) 2013-09-19 2021-04-06 Allovate, Llc Toothpaste for delivery of allergens to oral mucosa
US11980664B2 (en) 2013-09-19 2024-05-14 Allovate, Llc Toothpaste for delivering allergens to oral mucosa
EP2952200A1 (fr) 2014-06-04 2015-12-09 Alk-Abelló A/S Allergène pour le traitement prophylactique d'une allergie
WO2015185684A1 (fr) 2014-06-04 2015-12-10 Alk-Abelló A/S Allergène pour traitement prophylactique d'allergie

Similar Documents

Publication Publication Date Title
EP2627355B1 (fr) Suppression d'une réponse immunitaire d'hypersensibilité à l'aide d'un antigène non apparenté issu d'une matière source d'allergène
Roberts et al. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins
Weltzin et al. Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection
US20100255033A1 (en) Non-toxic double mutant forms of pertussis toxin as adjuvants
EP2627354B1 (fr) Suppression d'une réponse immunitaire d'hypersensibilité de type 1 par un antigène non apparenté
JP2023503057A (ja) ヘモフィルス・パラスイスに対する新規ワクチン
CA2466937C (fr) Antigene mycobacterien recombinant de type hemagglutinine de liaison a l'heparine methylee, procedes de preparation et compositions immunogenes comprenant un tel antigene
US20240115693A1 (en) Sars-cov-2 antigen nanoparticles and uses there of
Zei et al. Immunogenicity of trivalent subunit and split influenza vaccines (1989–90 winter season) in volunteers of different groups of age
WO2010128364A1 (fr) Procédé pour la prévention ou le traitement d'une allergie au pollen de taxodiaceae
JP5101795B2 (ja) 免疫モジュレーターとしての全細菌細胞
US9119803B2 (en) Carious tooth vaccine and preparation method
EP2359850A1 (fr) Vaccins unitemporels
Moschos et al. Comparative immunomodulatory properties of a chitosan-MDP adjuvant combination following intranasal or intramuscular immunisation
CN112423784A (zh) 用于治疗与异常的il-4和/或il-13表达或活性相关的病症的包含il-4和/或il-13的免疫原性产品
CN101411872A (zh) 预防龋齿的疫苗试剂盒及其使用方法
Riedmann et al. Effectiveness of engineering the nontypeable Haemophilus influenzae antigen Omp26 as an S-layer fusion in bacterial ghosts as a mucosal vaccine delivery
US20100086569A1 (en) Use of a first house dust mite group 2 allergen for treating allergy to a second house dust mite group 2 allergen
CN109310747B (zh) 恰加斯抗原及其抗体和组合物、方法和用途
JPH06507420A (ja) 粘膜の病原体に対するワクチンとその製法
Faure et al. Use of bacterial ribosomal immunostimulators in respiratory tract infections
WO2006095176A2 (fr) Formulation de vaccin
KR20020065497A (ko) 가축에서 유선 분비 항체의 생산
WO2004028561A1 (fr) Procede d'induction de reponses immunitaires
Sedaghat et al. Determination of bactericidal activity of serum against Vibrio cholerae outer membrane vesicles in BALB/c mice

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09786850

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09786850

Country of ref document: EP

Kind code of ref document: A1